The transforming growth factor-β (TGF-β) family regulates cell proliferation, differentiation, extracellular matrix synthesis, and apoptosis, which are all important processes in COPD pathogenesis. Attenuation of TGF-β signaling leads to pulmonary emphysema in animal models,[@bib1], [@bib2] which may reflect TGF-β1 effects on vascular endothelial growth factor and angiogenesis.[@bib3], [@bib4] TGF-β1 also has a pivotal role in maintaining peripheral tolerance against self-antigens[@bib5] and controlling autoimmune responses.[@bib6], [@bib7]

The TGF-β superfamily has several members: TGF-β exists as three isoforms---TGF-β1, TGF-β2, and TGF-β3---which exhibit similar functions in vitro but may have distinct activities in vivo.[@bib8] TGF-βs act through specific receptors (TGF-β receptors \[TGF-βRs\]) I, II, and III. All TGF-βs bind a heteromeric type I/II receptor complex, which activates both "canonical" signals involving SMADs (small mother against decapentaplegic) and "noncanonical" pathways involving mitogen-activated protein kinases (MAPKs) and phosphoinositide 3-kinase (PI3K).[@bib9]

The SMAD family of transcription factors consists of the receptor-regulated SMADs, a common pathway SMAD, and inhibitory SMADs. Receptor-regulated SMADs include SMAD2 and SMAD3, which are recognized by TGF-βRs and activin receptors, and SMADs 1, 5, 8, and 9, which are activated by bone morphogenetic protein (BMP) receptors. SMAD4 or cooperating SMAD is not phosphorylated by the TGF-βRs, whereas inhibitory SMADs (anti-SMADs), including SMAD6 and SMAD7, downregulate TGF-β signaling. SMADs also act as signal integrators and interact with MAPK, nuclear factor-κB, PI3K, and hypoxia-inducible factor 1 signaling pathways.[@bib8], [@bib10]

TGF-βRIII (also known as β-glycan) acts as a coreceptor and directly binds TGF-β1, 2, and 3 to enhance their binding to the TGF-βRI/II complex and increase SMAD-dependent signaling.[@bib11] TGF-β signaling is modulated by connective tissue growth factor (CTGF or CCN2). CNN directly binds TGF-β1 and facilitates binding to the TGF-βRI/II complex enhancing downstream signaling.[@bib12]

The latency-associated peptide (LAP) is associated with latent TGF-β binding proteins (LTBPs) forming a complex known as the large latent complex (LLC).[@bib13], [@bib14] Most TGF-β is secreted as part of the LLC. LTBPs belong to the fibrillin-LTBP family of extracellular matrix (ECM) proteins. LTBP-1 anchors to the ECM and creates traction when LAP binds cell surface integrins; this traction deforms LAP, which releases active TGF-β.[@bib13], [@bib15]

Conversely, TGF-βR-associated binding protein (TRAP) 1 inhibits TGF-β1 function by interfering with SMAD3 signaling.[@bib16] The 5′-TG-3′-interacting factors (TGIFs), TGIF1 and TGIF2, cause repression of TGF-β1-activated genes by direct competition with Smad2.[@bib17] In addition, BMP and activin membrane-bound inhibitor (BAMBI) acts as a competitive receptor antagonist for TGF-βRI.[@bib18] BAMBI expression is upregulated by TGF-β1 in a feedback loop.[@bib19] TGF-β-induced protein (TGFBI, also known as BIG-H3 and keratoepithelin) is an extracellular matrix protein used as a TGF-β1 bioactivity marker.[@bib20]

The aim of this study is to investigate the expression of TGF-β signaling pathways in the lower airways (bronchial mucosa and peripheral lung) of patients with stable COPD and control subjects.

Methods {#sec1}
=======

Subjects {#sec1.1}
--------

All patients with COPD and healthy control subjects were recruited from the Respiratory Medicine Unit of the Istituti Clinici Scientifici Maugeri, Veruno, Italy and the Section of Respiratory Diseases of the University Hospital of Ferrara, Italy. Archival material was used in the present study.[@bib21] We obtained bronchial biopsy samples from 55 subjects to study immunohistochemically. The characteristics of these subjects are reported in [Table 1](#tbl1){ref-type="table"}. Twenty-four subjects undergoing lung resection for a solitary peripheral neoplasm were recruited for the immunohistochemical study of peripheral lung tissue. The characteristics of these subjects are reported in [Table 2](#tbl2){ref-type="table"}. COPD and chronic bronchitis were defined according to international guidelines, that is, COPD is the presence of a postbronchodilator FEV~1~/FVC ratio \< 70% and chronic bronchitis is the presence of cough and sputum production for at least 3 months in each of two consecutive years according to Global Initiative for Chronic Obstructive Lung Disease criteria (<http://www.goldcopd.org>). In patients with COPD, the severity of the airflow obstruction was graded using the 2011 GOLD criteria. The GOLD criteria used here to stratify the severity of stable COPD was based on the degree of airflow obstruction, as symptoms and exacerbation rate data were not collected routinely before 2012. Furthermore, the addition of the symptoms and the number of exacerbations are of unproved value in designing studies on the pathogenesis of COPD.Table 1Clinical Characteristics of Subjects for Immunohistochemical Studies on Bronchial Biopsy SamplesGroupNo.Age (y)Male/FemalePack-years of SmokingEx/Current SmokersFEV~1~ (% Predicted) Pre-β~2~FEV~1~ (% Predicted) Post-β~2~FEV~1~/FVC (%)Control nonsmokers1167 ± 1010/100116 ± 14ND85 ± 10Control smokers with normal lung function1261 ± 79/343 ± 262/10104 ± 13ND81 ± 6COPD grades I and II (mild/moderate)1467 ± 812/240 ± 195/966 ± 14[a](#tbl1fna){ref-type="table-fn"}72 ± 1260 ± 8[a](#tbl1fna){ref-type="table-fn"}COPD grades III and IV (severe/very severe)1866 ± 911/754 ± 3613/535 ± 8[a](#tbl1fna){ref-type="table-fn"}^,^[b](#tbl1fnb){ref-type="table-fn"}38 ± 944 ± 10[a](#tbl1fna){ref-type="table-fn"}^,^[b](#tbl1fnb){ref-type="table-fn"}[^1][^2][^3][^4][^5]Table 2Characteristics of Subjects for Immunohistochemical Studies on the Peripheral Lung TissueGroupsNo.Age (y)Male/FemaleEx/Current SmokersPack-Years of SmokingChronic BronchitisFEV~1~ (% Predicted)FEV~1~/FVC (%)Control smokers1263.6 ± 310/26/651.3 ± 11.6No87.9 ± 4.577.4 ± 1.7Patients with COPD1269.9 ± 1.312/06/645.8 ± 6.1No68.6 ± 4.2[a](#tbl2fna){ref-type="table-fn"}58.7 ± 2.5[a](#tbl2fna){ref-type="table-fn"}[^6][^7]

All patients with COPD were stable, and none of the subjects with COPD were treated with theophylline, antibiotics, antioxidants, mucolytic agents, or glucocorticoids, or any combination thereof, in the month prior to bronchoscopy or lung resection. The study conformed to the Declaration of Helsinki and was approved by the institutional review boards of Istituti Clinici Scientifici Maugeri (protocol p81) and the University Hospital of Ferrara.

Other Methods {#sec1.2}
-------------

A detailed description of the lung function and fiberoptic bronchoscopy results; the collection, processing, and immunohistochemical analysis of the bronchial biopsy samples and the peripheral lung ([e-Tables 1, 2](#appsec1){ref-type="sec"}); and the statistical analysis are provided in [e-Appendix 1](#appsec1){ref-type="sec"}.

Results {#sec2}
=======

Clinical Characteristics of Subjects Providing Bronchial Biopsy and Peripheral Lung Samples {#sec2.1}
-------------------------------------------------------------------------------------------

We obtained and studied bronchial biopsy samples from 55 subjects. Thirty-two subjects had mild/moderate or severe stable COPD, 12 were current or ex-smokers with normal lung function, and 11 were lifelong nonsmokers with normal lung function ([Table 1](#tbl1){ref-type="table"}). In addition, we studied peripheral lung tissue from 24 subjects: 12 smokers with mild/moderate stable COPD and 12 smokers with normal lung function ([Table 2](#tbl2){ref-type="table"}).

Measurement of the Inflammatory Cells in the Bronchial Lamina Propria of COPD and Control Subjects {#sec2.2}
--------------------------------------------------------------------------------------------------

The data obtained from patients with stable COPD by immunohistochemical analysis confirmed previous results[@bib21] showing elevated numbers of CD8^+^ T cells, CD68^+^ macrophages, and neutrophils in COPD.

Immunohistochemical Results for TGF-β Signaling Pathway Members in the Bronchial Epithelium {#sec2.3}
-------------------------------------------------------------------------------------------

No differences in the expression of TGF-β1, TGF-β2, TGF-β3, TGF-βRI, TGF-βRII, TGF-βRIII, TGFβ-I/BIGH3, TGIF2, SMAD2, SMAD3, SMAD6, SMAD7, CCN2, LTBP-1, or TRAP-1 were seen in the bronchial epithelia of subjects with COPD compared with nonsmoking control subjects. The number of BAMBI^+^ immunostained cells was significantly increased in the bronchial epithelia of subjects with COPD compared with control subjects ([Fig 1](#fig1){ref-type="fig"}A-E, [Table 3](#tbl3){ref-type="table"}).Figure 1Photomicrographs showing the bronchial mucosa from (A) control nonsmoker, (B) control healthy smoker with normal lung function, (C) mild/moderate stable COPD, (D) severe/very severe stable COPD immunostained for identification of BAMBI^+^ cells (arrows) in the epithelium and bronchial lamina propria. Results are representative of those from 11 nonsmokers, 12 healthy smokers, 14 subjects with mild/moderate COPD, and 18 subjects with severe/very severe COPD. Graphs indicate median (interquartile range) values of (E) BAMBI scored in the epithelium, BAMBI (score), and (F) BAMBI^+^ cells quantified in the lamina propria (BAMBI/mm^2^) of the groups of subjects studied. *P* values were obtained using the Mann-Whitney test for comparison between groups. BAMBI = bone morphogenetic proteins and activin membrane-bound inhibitor.Table 3Immunohistochemical Quantification of TGF-β Signaling Pathways in Bronchial Biopsy SamplesTargetNonsmokers With Normal Lung FunctionSmokers With Normal Lung FunctionMild/Moderate COPDSevere/Very Severe COPDKruskal-Wallis\
*P* ValueBronchial epithelium score (0-3) TGF-β10.25 (0.0-0.75)0.25 (0.0-0.75)0.25 (0.0-1.0)0.37 (0.0-0.75).945 TGF-β20.12 (0.0-1.5)0.0 (0.0-1.5)0.0 (0.0-1.5)0.25 (0.0-2.0).846 TGF-β30.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0)n.v. TGF-βRI0.0 (0.0-0.25)0.0 (0.0-0.25)0.0 (0.0-1.0)0.0 (0.0-0.25).661 TGF-βRII0.5 (0.2-2.0)0.5 (0.0-3.0)0.5 (0.0-2.0)1.0 (0.0-2.0).405 TGFβ-RIII0.25 (0.0-0.5)0.25 (0.0-0.75)0.25 (0.0-1.0)0.25 (0.0-0.75).334 TGFBI/BIGH30.0 (0.0-0.0)0.0 (0.0-0.25)0.0 (0.0-0.0)0.0 (0.0-0.25).971 TGIF21.5 (1.25-2.0)1.5 (0.75-1.75)1.75 (0.75-2.5)1.5 (1.0-2.0).185 SMAD21.0 (0.0-2.5)0.5 (0.0-3.0)0.0 (0.0-2.0)1.0 (0.0-2.5).249 SMAD31.0 (0.0-2.0)0.0 (0.0-3.0)0.5 (0.0-1.5)1.0 (0.0-2.5).468 SMAD60.50 (0.25-1.0)0.50 (0.0-1.5)0.75 (0.0-1.5)0.25 (0.25-1.25).296 SMAD70.75 (0.0-2.0)0.5 (0.0-2.5)0.35 (0.0-2.5)0.5 (0.0-2.0).797 CCN21.5 (1.0-1.5)1.5 (1.0-2.5)1.75 (1.0-3.0)1.5 (1.0-2.5).866 LTBP-10.25 (0.0-0.25)0.0 (0.0-0.25)0.25 (0.0-0.75)0.25 (0.0-0.5).263 TRAP-10.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0)n.v. BAMBI0.5 (0.25-1.25)0.5 (0.25-0.75)1.0 (0.25-1.75)[a](#tbl3fna){ref-type="table-fn"}0.75 (0.25-1.5)[b](#tbl3fnb){ref-type="table-fn"}.033Bronchial lamina propria score (cells/mm^2^) TGF-β127.0 (5.0-60.0)12.5 (0.0-143.0)16.0 (0.0-64.0)28.0 (5.0-141.0).752 TGF-β228.0 (14.0-69.0)13.0 (0.0-37.0)19.5 (0.0-56.0)23.0 (0.0-68.0).211 TGF-β30.0 (0.0-13.0)16.0 (6.0-58.0)[a](#tbl3fna){ref-type="table-fn"}10.0 (0.0-39.0)[a](#tbl3fna){ref-type="table-fn"}4.5 (0.0-65.0)[b](#tbl3fnb){ref-type="table-fn"}.007 TGF-βRI5.0 (0.0-52.0)6.0 (0.0-75.0)13.0 (0.0-97.0)5.0 (0.0-73.0).186 TGF-βRII74.0 (0.0-225.0)48.0 (0.0-216.0)72.5 (8.0-505.0)45.0 (0.0-376.0).528 TGF-βRIII6.0 (4.0-23.0)6.0 (0.0-32.0)11.0 (0.0-97.0)8.0 (5.0-121.0).612 TGFBI/BIGH3251.0 (138-484)304.0 (174-548)338.0 (218-408)361.0 (244-468).142 TGIF2204 (64-352)169 (77-277)177 (77-322)157 (122-235).712 SMAD2181.5 (0.0-750.0)166.5 (50.0-514.0)51.0 (0.0-960.0)91.5 (4.0-627.0).530 SMAD377.0 (0.0-690.0)87.0 (6.0-754.0)111.0 (0.0-909.0)120.0 (0.0-353,0).822 SMAD645.5 (12.0-145.0)60.5 (12.0-148.0)83.0 (21.0-134.0)32.0 (9.0-148.0).143 SMAD767.0 (11.0-300.0)48.5 (0.0-584.0)96.0 (0.0-520.0)56.5 (0.0-620.0).949 CCN2147.0 (84.0-210.0)86 (52.0-234.0)111.0 (55.0-312.0)102.0 (48.0-168.0).768 LTBP-13.0 (0.0-13.0)1.5 (0.0-8.0)5.0 (0.0-65.0)[b](#tbl3fnb){ref-type="table-fn"}9.5 (0.0-109.0)[b](#tbl3fnb){ref-type="table-fn"}.017 TRAP-10.0 (0.0-6.0)0.0 (0.0-5.0)0.0 (0.0-12.0)0.0 (0.0-5.0).243 BAMBI16.0 (7.0-86.0)26.0 (8.0-35.0)53.0 (24.0-364.0)[a](#tbl3fna){ref-type="table-fn"}^,^[b](#tbl3fnb){ref-type="table-fn"}48.5 (16.0-258.0)[a](#tbl3fna){ref-type="table-fn"}^,^[b](#tbl3fnb){ref-type="table-fn"}.0001[^8][^9][^10][^11][^12]

Immunohistochemical Results for TGF-β Signaling Pathway Members in the Lamina Propria {#sec2.4}
-------------------------------------------------------------------------------------

No differences in TGF-β1, TGF-β2, TGF-βRI, TGF-βRII, TGF-βRIII, TGFBI/BIGH3, TGIF2, SMAD2, SMAD3, SMAD6, SMAD7, CCN2, or TRAP-1 expression were observed between groups in the lamina propria ([Table 3](#tbl3){ref-type="table"}).

The number of TGF-β3^+^ immunostained cells was significantly increased in the bronchial lamina propria of patients with mild/moderate COPD and control smokers with normal lung function compared with nonsmoking control subjects ([Table 3](#tbl3){ref-type="table"}). However, subjects with severe/very severe COPD had significantly decreased TGF-β3^+^ cells compared with control smokers with normal lung function. LTBP-1^+^ immunostaining ([Table 3](#tbl3){ref-type="table"}) and the number of BAMBI^+^ cells were significantly increased in all severities of COPD compared with control subjects ([Fig 1](#fig1){ref-type="fig"}A-F, [Table 3](#tbl3){ref-type="table"}). No differences in TGF-β1, TGF-β2, TGF-βRI, TGF-βRII, TGF-βRIII, TGFBI/BIGH3, TGIF2, SMAD2, SMAD3, SMAD6, SMAD7, CCN2, or TRAP-1 expression were observed between groups in the lamina propria.

Immunohistochemical Results of the TGF-β Signaling Pathway in the Peripheral Lung {#sec2.5}
---------------------------------------------------------------------------------

At variance with the bronchial epithelium, the percentage of TGF-β1^+^ ([Fig 2](#fig2){ref-type="fig"}A, [e-Fig 1](#appsec1){ref-type="sec"}), TGF-β3^+^ ([Fig 2](#fig2){ref-type="fig"}E, [e-Fig 2](#appsec1){ref-type="sec"}), and CCN2^+^ ([Fig 2](#fig2){ref-type="fig"}G, [e-Fig 3](#appsec1){ref-type="sec"}) bronchiolar epithelial cells in the peripheral airways was significantly decreased in patients with COPD compared with control smokers with normal lung function ([Table 4](#tbl4){ref-type="table"}). The percentage of TGF-β1^+^ alveolar macrophages was decreased in patients with COPD compared with control smokers with normal lung function ([Fig 2](#fig2){ref-type="fig"}B, [Table 4](#tbl4){ref-type="table"}). There was also a trend for decreased TGF-β3^+^ and CCN2^+^ immunostained alveolar macrophages in patients with COPD ([Figs 2](#fig2){ref-type="fig"}F, [2](#fig2){ref-type="fig"}H, [Table 4](#tbl4){ref-type="table"}). No other significant differences were observed between groups for any other molecules studied ([Fig 2](#fig2){ref-type="fig"}, [Table 4](#tbl4){ref-type="table"}, [e-Fig 4](#appsec1){ref-type="sec"}).Figure 2The percentage of the (A) bronchiolar epithelial and (B) alveolar macrophage cells immunostained for TGF-β1 and (G and H) CCN2 (CTGF). Values for (C and D) TGF-β2 and (E and F) TGF-β3 are shown. Results are representative of those from 12 subjects with stable COPD and 12 control smokers with normal lung function. The Mann-Whitney U test was used for statistical analysis. Exact *P* values are shown above each graph.Table 4Immunohistochemical Quantification of TGF-β Signaling Pathways in the Peripheral LungLocalization and AntigenControl SmokersCOPDMann-Whitney *U* Test *P* ValueBronchiolar epithelium (cells, percentage) TGF-β195.5 (69.8-98.8)68.0 (37.0-88.0).0266 TGF-β273.0 (40.8-94.0)12.5 (2.3-90.3).1651 TGF-β37.0 (2.3-81.8)2.5 (0.4-5.0).0321 TGF-β-RI85.0 (80.0-92.3)91.5 (84.0-96.5).1081 TGF-β-RII (bronchiolar smooth muscle)15.5 (8.3-23.5)11.0 (0.5-20.3).4003 TGF-βRIII0.0 (0.0-0.0)0.0 (0.0-0.0)NA TGIF2 (nuclear)3.0 (0.0-21.0)12.5 (7.5-19.8).1623 TGIF2 (apical)60.0 (34.5-85.3)52.5 (45.5-73.0).9539 SMAD2 (nuclear)9.0 (4.0-21.5)6.0 (1.3-34.8).7947 SMAD2 (cytosolic)10.5 (1.5-22.5)1.0 (0.0-7.8).0610 SMAD35.0 (2.3-30.8)15.5 (1.0-45.5).7066 SMAD6100.0 (99.8-100.0)100.0 (99.2-100.0).6148 SMAD799.0 (97.3-99.7)99.0 (93.0-99.0).5516 TRAP-1 (nuclear)5.0 (0.3-12.8)6.0 (0.3-15.5).8612 TRAP-1 (cytosolic)0.0 (0.0-0.0)0.0 (0.0-7.5).4255 CCN2100.0 (98.8-100.0)73.5 (43.8-92.8).0017 LTBP-10.0 (0.0-0.0)0.0 (0.0-0.0).8939 BAMBI (nuclear)55.5 (38.2-75.1)51.3 (40.0-60.3).5833 BAMBI (cytosolic)4.0 (2.1-6.6)3.5 (1.2-5.8).5031Alveolar macrophages (cells, percentage) TGF-β198.5 (90.5-99.8)63.0 (50.0-66.0).0145 TGF-β293.0 (84.0-98.0)88.5 (55.5-95.0).2843 TGF-β390.5 (61.5-98.0)61.0 (17.8-79.8).0528 TGF-βRI87.5 (34.0-93.5)85.0 (70.8-97.8).5435 TGF-βRII11.0 (0.0-40.5)29.5 (12.0-47.8).1737 TGF-βRIII18.0 (11.0-63.8)42.5 (20.8-76.0).2850 TGIF2 (nuclear)7.5 (2.3-23.0)7.5 (1.3-15.8).7501 TGIF2 (cytosolic)73.5 (45.3-93.3)73.5 (72.3-81.0).9769 SMAD2 (nuclear)0.0 (0.0-0.0)0.0 (0.0-1.8).3496 SMAD2 (cytosolic)63.0 (41.0-82.0)60.5 (39.3-85.8).9770 SMAD3 (nuclear)0.0 (0.0-1.0)0.0 (0.0-1.0).9175 SMAD3 (cytosolic)39.5 (32.0-68.3)27.0 (10.0-79.8).4024 SMAD6100.0 (100.0-100.0)100.0 (100.0-100.0)NA SMAD7100.0 (100.0-100.0)100.0 (100.0-100.0).3384 TRAP-1 (nuclear)14.0 (11.0-19.0)22.5 (1.8-24.0).1558 TRAP-1 (cytosolic)79.0 (65.0-82.8)76.5 (63.0-79.5).3545 CCN298.0 (94.5-100.0)90.5 (87.8-98.9).0506 LTBP-129.5 (15.8-46.5)45.0 (29.5-77.3).1120 BAMBI (nuclear)53.8 (7.0-66.8)18.5 (10.8-31.1).0832 BAMBI (cytosolic)32.5 (24.2-40.0)42.5 (26.0-59.5).2038Lung vessels (score) TGFBI/BIGH31.0 (1.0-1.8)1.0 (1.0-2.0).3132 SMAD21.0 (1.0-2.0)1.5 (1.0-2.8).3440[^13][^14][^15]

Analysis of Gene Expression Data in Large and Small Airway Epithelial Cells {#sec2.6}
---------------------------------------------------------------------------

We examined the relative expression of TGF-β1, TGF-β2, TGF-β3, CCN2, LTBP1, and BAMBI mRNA in epithelial cells from the small (GSE11784) and large airways (GSE37147) of patients with COPD compared with control subjects ([e-Table 3](#appsec1){ref-type="sec"}) using previously published data sets. These data demonstrated a lack of concordance between protein and mRNA for TGF-β pathway members (compare results in [e-Table 4](#appsec1){ref-type="sec"} with those in [Tables 3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"}). BAMBI mRNA expression was not different between bronchial epithelial cells from subjects with COPD (n = 30) and healthy smokers (n = 69), although active smoking had a small significant (adjusted *P* = .03) 1.14-fold increase in BAMBI mRNA ([e-Table 3](#appsec1){ref-type="sec"}). In contrast, LTBP-1 mRNA expression in subjects with COPD was significantly less than that in nonsmokers (adjusted *P* = 8.74 × 10^--14^).

In contrast to the reduction in TGF-β1, TGF-β3, and CCN2 protein expression in COPD compared with cells from healthy smokers, there was no difference in TGF-β3 mRNA in small airway epithelial cells, but there was an increase in TGF-β1 and CCN2 mRNA expression ([e-Table 3](#appsec1){ref-type="sec"}). TGF-β1 mRNA expression was significantly increased at 1.22-fold (adjusted *P* = .00194) and CCN2 was increased by 1.3-fold (adjusted *P* = .0024) in cells from subjects with COPD (n = 36) vs those from healthy nonsmokers (n = 69).

Correlations Between Clinical Parameters, Inflammatory Cell Counts, and TGF-β Signaling Pathway in Bronchial Biopsy Samples {#sec2.7}
---------------------------------------------------------------------------------------------------------------------------

There was a significant correlation between the number of cigarettes smoked (pack-years) and the number of TGF-β3^+^ immunostained cells/mm^2^ in the bronchial lamina propria when subjects with or without COPD were grouped together ([Fig 3](#fig3){ref-type="fig"}A). This correlation was maintained within the COPD group alone ([Fig 3](#fig3){ref-type="fig"}B). The numbers of BAMBI^+^ immunostained cells/mm^2^ in the bronchial lamina propria were significantly correlated with numbers of CD8^+^ cells/mm^2^ ([Fig 3](#fig3){ref-type="fig"}C) and CD68^+^ cells/mm^2^ ([Figure 3](#fig3){ref-type="fig"}D). No other significant correlations were observed between groups for all the other molecules studied.Figure 3Regression analysis between pack-years and number of TGF-β3^+^ cells infiltrating the bronchial lamina propria in (A) all smokers (with and without COPD) and (B) patients with COPD alone. In the latter patients, there is a significant positive correlation between the number of BAMBI^+^ cells in the bronchial lamina propria and those of (C) CD8^+^ and (D) CD68^+^ cells. Correlation coefficients were calculated by using the Spearman rank method. See [Figure 1](#fig1){ref-type="fig"} legend for expansion of abbreviations.

Discussion {#sec3}
==========

We report here for the first time, to our knowledge, the comprehensive expression and localization of TGF-β regulatory proteins in the lower airways of patients with stable COPD compared with control subjects. We observed decreased expression of TGF-β1 and TGF-β3 in the bronchiolar but not bronchial epithelium and of TGF-β1 in alveolar macrophages of patients with stable COPD compared with control smokers with normal lung function. Furthermore, TGF-β3 expression was increased in the bronchial lamina propria of control smokers with normal lung function and mild/moderate stable COPD compared with control nonsmokers and correlated significantly with pack-years. These data suggest that the TGF-β signaling is selectively impaired in the small airway epithelia of patients with stable COPD. The expression of the TGF-β pseudoreceptor BAMBI was also elevated in the bronchial mucosa of patients with COPD.

Conflicting results have previously been reported regarding the expression of the TGF-β signaling pathway in patients with stable COPD in bronchial biopsy samples and peripheral lung ([e-Table 4](#appsec1){ref-type="sec"}). Our data for TGF-β1 agree with some previous studies[@bib22], [@bib23] but not others.[@bib24], [@bib25] The latter studies found increased TGF-β1 expression in the small airway and alveolar epithelial cells, but when the control subjects used for the study are classified according to current GOLD criteria using FEV~1~/FVC ratios, many would be reclassified as having COPD.[@bib24] Another study reported increased TGF-β1 protein for both COPD and control smokers compared with nonsmoking subjects.[@bib26] A more recent study found increased release of total TGF-β1 from bronchial epithelium in vitro obtained from patients with COPD compared with control subjects without any significant differences in active TGF-β1 release.[@bib27] Finally, another study found no significant differences in BAL TGF-β1 levels between patients with COPD and control subjects.[@bib28] These apparent discrepancies may be explained by incomplete clinical features or the selectivity of the primary anti-TGF-β1 antibodies used, or both.[@bib29], [@bib30]

Llinàs et al[@bib31] observed decreased TGF-β1 mRNA expression in the peripheral lungs of patients with severe stable COPD compared with control nonsmoking subjects, and in agreement with our present data, Kokturk et al[@bib32] found no difference in TGF-β1 immunohistochemical expression in the bronchial biopsy samples from patients with stable COPD and control nonsmoking subjects. Vignola et al[@bib33] demonstrated increased TGF-β1 immunostaining in the bronchial biopsy samples of patients with chronic bronchitis compared with control young nonsmoking subjects (mean age, 46 years). However, these patients had a mean FEV~1~ of 56% to 90% predicted, but only nine subjects were considered to have COPD using unspecified criteria.[@bib33] Hence, these differences render the comparison of our results with the previous studies difficult.[@bib33], [@bib34] Decreased expression of TGF-β1 in the small airways in COPD shown here and its critical role in regulating self-tolerance[@bib5] may explain the autoimmunity seen in some patients with COPD.[@bib6], [@bib7] The complex signaling control points within the TGF-β activation pathway may enable targeted treatment of this complication.

TGF-β3 expression was increased in the bronchial lamina propria of patients with COPD and control smokers compared with control nonsmoking subjects, although TGF-β3^+^ cells were decreased in patients with severe/very severe COPD compared with control smokers. There was a significant correlation between pack-years and the number of TGF-β3^+^ immunostained cells/mm^2^ in the bronchial lamina propria. To our knowledge, this is the first report of TGF-β3 protein expression and localization in the lower airways of patients with stable COPD and is in keeping with the results of decreased TGF-β3 mRNA expression in the peripheral lung of patients with more severe COPD[@bib31], [@bib35] and of increased TGF-β3 mRNA expression in the peripheral lung of smokers compared with nonsmokers.[@bib31] This concordance was not observed with our present mRNA results.

TGF-β3 protein release from bronchial epithelium in vitro and BAL TGF-β3 levels were similar between patients with COPD and control subjects.[@bib27], [@bib28] We were unable to find any significant differences between patients with stable COPD and control subjects in TGF-β2 and TGF-βR expression and localization in the lower airways. In addition, we could not confirm the decreased TGF-βRI protein expression observed in the peripheral lungs of patients with moderate stable COPD compared with control subjects in previous studies.[@bib23], [@bib31] This discrepancy may be explained by differences in anti-TGF-βRI antibody used. In contrast, our results on TGF-βRII protein expression are in agreement with the data from the same study[@bib23]and with the mRNA data from Llinàs et al.[@bib31]

To our knowledge, we have provided the first data on TGF-βRIII protein expression, showing its low immune expression in the lower airways of patients with stable COPD and control subjects. Single nucleotide polymorphisms are likely to be associated with decreased TGF-βRIII function and are linked to an increased risk of pulmonary emphysema developing.[@bib36] This area requires further research.

We found no significant differences between patients with stable mild/moderate COPD and control subjects (including smokers with normal lung function) in SMAD2, SMAD3, SMAD6, and SMAD7 expression and localization in the lower airways, confirming previous studies.[@bib23], [@bib37], [@bib38] In contrast, reduced SMAD6 and SMAD7 mRNA expression was reported in bronchial biopsy samples from patients with stable COPD,[@bib39] as well as decreased SMAD7 mRNA in the bronchial epithelium[@bib40] and decreased SMAD mRNA expression[@bib41] and SMAD protein expression in the peripheral lung.[@bib42] These discrepancies may be explained by the lack of concordance between mRNA and protein, as we described in our study comparing gene expression data, or by the potential different pathogenic pathways behind the onset of COPD vs pulmonary emphysema.[@bib43], [@bib44], [@bib45] Overall, these data suggest limited involvement of SMAD signaling in the pathogenesis of lower airway inflammation and damage in patients with stable mild/moderate COPD.

We also demonstrated decreased CCN2 (CTGF) expression in the bronchiolar epithelium but not in the bronchial mucosa of patients with stable COPD compared with control smokers with normal lung function. Conflicting results have previously been reported for CCN2 mRNA expression in patients with COPD.[@bib31], [@bib46] TGF-β1 induces CCN2 expression in fibroblasts in vitro,[@bib47] suggesting that the decreased expression of both TGF-β1 and CCN2 observed in the bronchiolar epithelium of the patients in our study with stable COPD may be related. Lung specimens from subjects with a solitary peripheral neoplasm were used in the present study, raising the question as to whether lung tumors may influence the results. The presence of similar pathologic conditions in smokers and patients with COPD and the large number of studies already published examining inflammatory markers and cytokine pathways in similar sets of subjects support the use of these groups of patients for peripheral lung studies.

LTBP-1 is the only LTBP that both interacts with latent TGF-βs[@bib48] and is predominantly expressed in the lungs.[@bib49], [@bib50], [@bib51], [@bib52], [@bib53] LTBP-1 immunostaining was increased in the bronchial lamina propria of patients with COPD compared with control smokers with normal lung function. LTBP-1 may activate TGF-β3, but the concomitant upregulation of TGF-β3 observed in the bronchial lamina propria in our study is smoking related and not disease related, suggesting the presence of alternative mechanisms regulating the expression of these two molecules. In fact, a substantial amount of LTBP-1 can be secreted by cells without being bound to latent TGF-βs, and TGF-β-independent functions for LTBP-1 need to be determined.[@bib54]

We observed a marked increase in the expression of the TGF-β pseudoreceptor BAMBI in the bronchial mucosa but not in the peripheral airways of patients with stable COPD compared with control subjects in keeping with previous studies in COPD peripheral lung.[@bib55] There was a positive correlation between the number of BAMBI^+^ and CD8^+^ and CD68^+^ cells. These data are in keeping with the enhanced plasma BAMBI levels recently described in stable COPD that positively correlated with the blood Th17/regulatory T cells (Treg) ratio.[@bib56] In a mouse model of autoimmune arthritis, BAMBI deficiency protected mice against the development of disease by modulating Th17/Treg differentiation.[@bib57] This may account for the autoimmune and the Th17/Treg imbalance that we and others have previously described in the bronchial mucosa of patients with stable COPD.[@bib6], [@bib7], [@bib58]

The mechanisms regulating BAMBI expression are poorly understood. In vitro, BAMBI expression can be upregulated by TGF-β1.[@bib19] However, the discrepancy observed between TGF-β1 and BAMBI expression in the different compartments of the lower airways suggest that non-TGF-β1-dependent pathways could be involved in BAMBI upregulation in stable COPD. As a potential limitation of this study, we did not apply multiple corrections in the statistical analysis of differences between groups for our "ex vivo" data of the lower airways. In fact, applying multiple corrections can lead to false-negative findings, but by not applying them, findings might be false positive. We were confident that applying a multiple test (analysis of variance or Kruskal-Wallis) followed by a "restricted" test analyzing differences between groups could be sufficiently stringent for identification of true differences.

In conclusion, the reported differences in TGF-β1 and BAMBI expression may contribute to the pathogenesis of stable COPD creating a microenvironment facilitating local autoimmune responses associated with COPD.

Supplementary Data {#appsec1}
==================

e-Online Data

**Author contributions:** A. D. S., G. C., I. M..A., F. L. M. R., and F. C., contributed to study design, interpretation of data, and writing the manuscript. P. J. B., K. F. C., P. B., P. M., P. R., S. P., Y. G., G. G., and B. B. contributed to critical revision of the manuscript. C. S., I. G., P. C., P. B., M. C., A. D. S., G. C., and A. P. contributed to the production of the data and accuracy of the data analysis.

**Financial/nonfinancial disclosures:** The authors have reported to *CHEST* the following: F. L. M. R. has served on the advisory boards of AstraZeneca, Novartis, and Mundipharma. He has served as a consultant for AstraZeneca, Boehringer Ingelheim, Chiesi, Mundipharma, Malesci-Guidotti, Novartis, and Teva and has received grants from AstraZeneca, Boehringer Ingelheim, Chiesi, and GlaxoSmithKline. A. P. reports grants, personal fees, or reimbursement for travel expenses from AstraZeneca, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Mundipharma, Novartis, Teva, Sanofi, and Zambon. None declared (A. D. S., C. S., I. G., P. C., P. B., M. C., P. M., P. R., G. G., F. C., S. P., Y. G., K. F. C., B. J. B., I. M. A, B. B., G. C.).

**Role of sponsors:** The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript.

**Additional information:** The e-Appendix, e-Figures, and e-Tables can be found in the Supplemental Materials section of the online article.

**FUNDING/SUPPORT:** This work was supported by Istituti Clinici Scientifici Maugeri, SpA, SB, IRCCS, Ricerca Corrente, FARs of the University of Ferrara (to G. C.). I. M. A. is supported by the BBSRC, the Wellcome Trust \[Grant 093080/Z/10/Z\], the Dunhill Medical Trust \[Grant R368/0714\], and the MRC-ABPI COPD-MAP consortium \[Grant G1001367/1\].

[^1]: Patients with COPD were classified according to Global Initiative for Chronic Obstructive Lung Disease 2011 (<http://www.goldcopd.org>) grades of severity using only the severity of airflow obstruction. For patients with COPD, FEV~1~/FVC (%) are postbronchodilator values.

[^2]: ND = not determined; pre-β~2~ = values obtained before bronchodilator use; post-β~2~ = values obtained after bronchodilator use.

[^3]: Statistical analysis with analysis of variance test:

[^4]: *P* \< .0001, which was significantly different from control smokers with normal lung function and control never-smokers.

[^5]: *P* \< .0001, which was significantly different from mild/moderate COPD.

[^6]: For COPD and control smoker subjects, FEV~1~ % predicted and FEV~1~/FVC % are postbronchodilator values. Data expressed as mean ± SEM.

[^7]: Analysis of variance = *P* \< .01.

[^8]: Data are expressed as median (range).

[^9]: BAMBI = bone morphogenetic protein and activin membrane-bound inhibitor. CTGF = connective tissue growth factor; LTBP-1 = latent transforming growth factor-β1 binding protein 1; n.v. = no value. SMAD = small mother against decapentaplegic TGFBI = transforming growth factor-β-induced protein; TGIF2 = TGF-β-induced factor 2; TRAP-1 = transforming growth factor-β receptor-associated binding protein.

[^10]: Statistics: The Kruskal-Wallis test was used for multiple comparisons followed by the Mann-Whitney *U* test for comparison between groups.

[^11]: *P* \< .05, which was significantly different from control nonsmokers.

[^12]: *P* \< .05, which was significantly different from control smokers.

[^13]: Data expressed as median (range).

[^14]: Statistics: The Mann-Whitney *U* test was applied for comparison between groups. Note: when not specified, the positive staining is intended to be nuclear, apart from TGFβ-RI, in which it is apical in the bronchiolar epithelium and cytosolic in the alveolar macrophages, and TGF-βRIII and LTBP-1, for which it is cytosolic.

[^15]: NA = not applicable. See [Table 3](#tbl3){ref-type="table"} legend for expansion of other abbreviations.
